FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MATHIS LARRY					AL	2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC ALXN								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				vner	
	25 KNOTTER DR					3. Date of Earliest Transaction (Month/Day/Year) 05/03/2007								Officer below)	(give title		Other (s below)	specify	
C/O ALEXION PHARMACEUTICALS INC (Street) CHESHIRE CT 06410 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					action	ction 2A. Deemed Execution Date,			3. Transacti Code (Ins	3. 4. Securi Transaction Disposed Code (Instr. 5)				5. Amou Securitie Benefici	nt of es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
		т		ve Securities Acquired, Disposed of, or Benefits, calls, warrants, options, convertible securit					eficially	ially Owned									
1. Title of Derivative Security (Instr. 3)	L. Title of 2. 3. Transaction 3A. Deemed Execution Date Security or Exercise (Month/Day/Year) if any			4. Transac	. 5. Number 6. ransaction of Exode (Instr. Derivative (M			options, converti			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	Ownershi Form: ly Direct (D) or Indirec (I) (Instr. 4		Beneficial Ownership t (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable	Expii Date	iration	Title	Amount or Number of Shares						
Option to Purchase Common Stock, par value \$.0001 per share	\$43.36	05/03/2007			A		7,500		(1)	05/03	3/2017	Common Stock, par value \$.0001 per share	7,500	\$43.36	7,500		D		

Explanation of Responses:

1. These options will vest in four quarterly installments of 1,875 options during the one year period commencing on May 3, 2007 and ending on May 3, 2008.

/s/ Larry Mathis

05/07/2007

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.